Search

Your search keyword '"Furman, R"' showing total 502 results
Start Over Author "Furman, R"
502 results on '"Furman, R"'

51. PATTERNS OF IDELALISIB TREATMENT-EMERGENT LYMPHOCYTOSIS IN PATIENTS WITH CLL OR SLL

Author

Ghia, P., Cheson, B. D., Furman, R. R., Hallek, M., Hillmen, P., O'Brien, S. M., Sharman, J. P., Dubowy, R. L., Velasco, B., Waldapfel, C. C., Zelenetz, A. D., Brown, J. R., Ghia, P., Cheson, B. D., Furman, R. R., Hallek, M., Hillmen, P., O'Brien, S. M., Sharman, J. P., Dubowy, R. L., Velasco, B., Waldapfel, C. C., Zelenetz, A. D., and Brown, J. R.

Published
2016

52. Creating Criminals: Australia's response to asylum seekers and refugees

Author

Furman, R, Lamphear, G, Epps, D, Briskman, L, Fiske, LI, Furman, R, Lamphear, G, Epps, D, Briskman, L, and Fiske, LI

Abstract

Perhaps more so than with many books, the title of our book, The Immigrant Other : Lived Experiences in a Transnational World, articulates our intentions for the overall nature of our volume and for each individual chapter. In this introduction ...

Published
2016

54. Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results

Author

Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., Coutre, S., Sharman, J., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Lamanna, N., Hallek, M., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T., Wagner, L., Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., Coutre, S., Sharman, J., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Lamanna, N., Hallek, M., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T., and Wagner, L.

Published
2015

55. Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors

Author

Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T., Stilgenbauer, S., Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T., and Stilgenbauer, S.

Published
2015

56. Results from the phase 2 RESONATE (TM)-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion

Author

Munir, T., O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D., Chu, A., Hallek, M., Stilgenbauer, S., Munir, T., O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D., Chu, A., Hallek, M., and Stilgenbauer, S.

Published
2015

57. Results from the phase 2 RESONATE (TM)-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p

Author

Stilgenbauer, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D. F., Chu, A. D., Hallek, M., O'Brien, S., Stilgenbauer, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D. F., Chu, A. D., Hallek, M., and O'Brien, S.

Published
2015

61. Caused motion events in Turkish: Verbal and gestural representation in adults and children

Author

Furman, R., Özyürek, A., Muysken, P.C., and Radboud University Nijmegen

Subjects
LOT Dissertation Series, Relations between modality and language structure. Insights from comparisons of sign languages and gestures [The development of representation of caused motion events in children’s speech and gesture (Project of], Relations between modality and language structure. Insights from comparisons of sign languages and gestures, Multimodal language and communication, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

Caused motion events (e.g. a boy pulls a box into a room) are basic events where an Agent (the boy) performs an Action (pulling) that causes a Figure (box) to move in a spatial Path (into) to a Goal (the room). These semantic elements are mapped onto lexical and syntactic structures differently across languages This dissertation investigates the encoding of caused motion events in Turkish, and the development of this encoding in speech and gesture. First, a linguistic analysis shows that Turkish does not fully fit into the expected typological patterns, and that the encoding of caused motion is determined by the fine-grained lexical semantics of a verb as well as the syntactic construction the verb is integrated into. A grammaticality judgment study conducted with adult Turkish speakers further establishes the fundamentals of the encoding patterns. An event description study compares adults’ verbal and gestural representations of caused motion to those of children aged 3 to 5. The findings indicate that although language-specificity is evident in children’s speech and gestures, the development of adult patterns takes time and occurs after the age of 5. A final study investigates a longitudinal video corpus of the spontaneous speech of Turkish-speaking children aged 1 to 3, and finds that language-specificity is evident from the start in both children’s speech and gesture. Apart from contributing to the literature on the development of Turkish, this dissertation furthers our understanding of the interaction between language-specificity and the multimodal expression of semantic information in event descriptions.

Published
2012

62. 21 SF3B1 MUTATIONS INDUCE ABERRANT SPLICING LEADING TO A BLOCK IN ERYTHROID DIFFERENTIATION AND COMPETITIVE ADVANTAGE

Author

Buonamici, S., primary, Perino, S., additional, Lim, K., additional, Darman, R., additional, Feala, J., additional, Peng, S., additional, Bhavsar, E., additional, Corson, L., additional, Keaney, G., additional, Mizui, Y., additional, Obeng, E., additional, Park, E., additional, Wang, J., additional, Warmuth, M., additional, Yu, L., additional, Zhu, P., additional, Furman, R., additional, Ebert, B., additional, and Smith, P., additional

Published
2015
Full Text
View/download PDF

63. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

Author

Osterborg, A., primary, Jewell, R. C., additional, Padmanabhan-Iyer, S., additional, Kipps, T. J., additional, Mayer, J., additional, Stilgenbauer, S., additional, Williams, C. D., additional, Hellmann, A., additional, Furman, R. R., additional, Robak, T., additional, Hillmenn, P., additional, Trn ny, M., additional, Dyer, M. J. S., additional, Piotrowska, M., additional, Kozak, T., additional, Gupta, I. V., additional, Phillips, J. L., additional, Goldstein, N., additional, Struemper, H., additional, Losic, N., additional, Lisby, S., additional, and Wierda, W. G., additional

Published
2015
Full Text
View/download PDF

64. Early language-specificity in Turkish children's caused motion event expressions in speech and gesture

Author

Furman, R., Özyürek, A., Küntay, A.C., Franich, K., Iserman, K.M., Keil, L.L., Franich, K., Iserman, K.M., and Keil, L.L.

Subjects
Relations between modality and language structure. Insights from comparisons of sign languages and gestures [The development of representation of caused motion events in children’s speech and gesture (Project of], Relations between modality and language structure. Insights from comparisons of sign languages and gestures, Communicative Competences
Abstract

Contains fulltext : 317558.pdf (Publisher’s version ) (Open Access)

Published
2010

66. EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Author

Stilgenbauer, S., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Hallek, M. J., Coiffier, B., O'Brien, S. M., Tausch, E., Kreuzer, K. A., Jiang, W., Jahn, T. M., Lazarov, M., Sharman, J. P., Stilgenbauer, S., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Hallek, M. J., Coiffier, B., O'Brien, S. M., Tausch, E., Kreuzer, K. A., Jiang, W., Jahn, T. M., Lazarov, M., and Sharman, J. P.

Published
2014

67. EFFECT OF IDELALISIB/RITUXIMAB COMBINATION TREATMENT OF RELAPSED CLL ON THE BCR SIGNALING-RELATED CHEMOKINES CCL3 AND CCL4: DATA FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Author

Ghia, P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Hallek, M. J., Coiffier, B., O'Brien, S. M., Stilgenbauer, S., Jiang, W., Jahn, T. M., Wong, M., Lazarov, M., Sharman, J. P., Ghia, P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Hallek, M. J., Coiffier, B., O'Brien, S. M., Stilgenbauer, S., Jiang, W., Jahn, T. M., Wong, M., Lazarov, M., and Sharman, J. P.

Published
2014

68. HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS

Author

Eradat, H. A., Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Cheson, B. D., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Lamanna, N., Hallek, M. J., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. M., Wagner, L. I., Eradat, H. A., Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Cheson, B. D., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Lamanna, N., Hallek, M. J., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. M., and Wagner, L. I.

Published
2014

69. Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL

Author

Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Cheson, B. D., Ruppert, S., Kroenig, H., Schuster, A., Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Cheson, B. D., Ruppert, S., Kroenig, H., and Schuster, A.

Published
2014

70. SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL

Author

Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H. A., Lamanna, N., Coiffier, B., Pettitt, A., Li, X., Jahn, T. M., O'Brien, S. M., Hallek, M. J., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H. A., Lamanna, N., Coiffier, B., Pettitt, A., Li, X., Jahn, T. M., O'Brien, S. M., and Hallek, M. J.

Published
2014

71. EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Author

Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Hillmen, P., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Stilgenbauer, S., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Hillmen, P., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., and Stilgenbauer, S.

Published
2014

72. 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia

Author

Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Ruppert, S., Schuster, A., Kroenig, H., Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Ruppert, S., Schuster, A., and Kroenig, H.

Published
2014

73. How does linguistic framing influence co-speech gestures? Insights from crosslinguistic differences and similarities

Author

Özyürek, A., Kita, S., Allen, S., Furman, R., Brown, A., Liebal, K., Mueller, C., Pika, S., Liebal, K., Mueller, C., and Pika, S.

Subjects
Research Donders Centre for Cognitive Neuroimaging, 110 000 Neurocognition of Language, Onderzoek Donders Centre for Cognitive Neuroimaging, Benjamins current topics, Relations between modality and language structure. Insights from comparisons of sign languages and gestures, Communicative Competences
Abstract

Contains fulltext : 275321.pdf (Publisher’s version ) (Closed access)

Published
2007

76. EFFICACY OF NUCLEO C. M. P. FORTE IN RESTORATIVE THERAPY AFTER NERVE INJURY.

Author

BARYLO, O. S., POLISHCHUK, S. S., FURMAN, R. L., and ZAKALATA, T. R.

Subjects
DRUG efficacy, DENTAL fillings, NERVOUS system injuries, ULTRASTRUCTURE (Biology), MANDIBULAR fractures, PATCH-clamp techniques (Electrophysiology)
Abstract

Copyright of Likarska Sprava is the property of J. Likarska Sprava and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2017
Full Text
View/download PDF

77. 456 SF3B1 mutations induce disease relevant aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibition

Author

Buonamici, S., primary, Lim, K., additional, Feala, J., additional, Darman, R., additional, Myint, K., additional, Park, E., additional, Aird, D., additional, Chan, B., additional, Fekkes, P., additional, Furman, R., additional, Keaney, G., additional, Kumar, P., additional, Kunii, K., additional, Puyang, X., additional, Thomas, M., additional, Mizui, Y., additional, Warmuth, M., additional, Zhu, P., additional, Yu, L., additional, and Smith, P., additional

Published
2014
Full Text
View/download PDF

78. PP-054 EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Author

Sharman, J., primary, Coutre, S., additional, Furman, R., additional, Cheson, B., additional, Pagel, J., additional, Hillmen, P., additional, Barrientos, J., additional, Zelenetz, A., additional, Kipps, T., additional, Flinn, I., additional, Ghia, P., additional, Hallek, M., additional, Coiffier, B., additional, O’Brien, S., additional, and Stilgenbauer, S., additional

Published
2014
Full Text
View/download PDF

84. Genetic diseases and molecular genetics

Author

Legendre, C., primary, Cohen, D., additional, Delmas, Y., additional, Feldkamp, T., additional, Fouque, D., additional, Furman, R., additional, Gaber, O., additional, Greenbaum, L., additional, Goodship, T., additional, Haller, H., additional, Herthelius, M., additional, Hourmant, M., additional, Licht, C., additional, Moulin, B., additional, Sheerin, N., additional, Trivelli, A., additional, Bedrosian, C. L., additional, Loirat, C., additional, Legendre, C., additional, Babu, S., additional, Jungraithmayr, T., additional, Lebranchu, Y., additional, Riedl, M., additional, Gaber, A. O., additional, Bedrosian, C., additional, Muus, P., additional, Douglas, K., additional, Remuzzi, G., additional, Kourouklaris, A., additional, Ioannou, K., additional, Athanasiou, I., additional, Demetriou, K., additional, Panagidou, A., additional, Zavros, M., additional, Rodriguez C, N. Y., additional, Blasco, M., additional, Arcal, C., additional, Quintana, L. F., additional, Rodriguez de Cordoba, S., additional, Campistol, J. M., additional, Bachmann, N., additional, Eisenberger, T., additional, Decker, C., additional, Bolz, H. J., additional, Bergmann, C., additional, Pesce, F., additional, Cox, S. N., additional, Serino, G., additional, De Palma, G., additional, Sallustio, F. P., additional, Schena, F., additional, Falchi, M., additional, Pieri, M., additional, Stefanou, C., additional, Zaravinos, A., additional, Erguler, K., additional, Lapathitis, G., additional, Dweep, H., additional, Sticht, C., additional, Anastasiadou, N., additional, Zouvani, I., additional, Voskarides, K., additional, Gretz, N., additional, Deltas, C. C., additional, Ruiz, A., additional, Bonny, O., additional, Sallustio, F., additional, Curci, C., additional, Cox, S., additional, Kemter, E., additional, Sklenak, S., additional, Aigner, B., additional, Wanke, R., additional, Kitzler, T. M., additional, Moskowitz, J. L., additional, Piret, S. E., additional, Lhotta, K., additional, Tashman, A., additional, Velez, E., additional, Thakker, R. V., additional, Kotanko, P., additional, Leierer, J., additional, Rudnicki, M., additional, Perco, P., additional, Koppelstaetter, C., additional, Mayer, G., additional, Sa, M. J. N., additional, Alves, S., additional, Storey, H., additional, Flinter, F., additional, Willems, P. J., additional, Carvalho, F., additional, Oliveira, J., additional, Arsali, M., additional, Papazachariou, L., additional, Demosthenous, P., additional, Lazarou, A., additional, Hadjigavriel, M., additional, Stavrou, C., additional, Yioukkas, L., additional, Deltas, C., additional, Pierides, A., additional, Kkolou, M., additional, Toka, H. R., additional, Dibartolo, S., additional, Lanske, B., additional, Brown, E. M., additional, Pollak, M. R., additional, Familiari, A., additional, Zavan, B., additional, Sanna Cherchi, S., additional, Fabris, A., additional, Cristofaro, R., additional, Gambaro, G., additional, D'Angelo, A., additional, Anglani, F., additional, Toka, H., additional, Mount, D., additional, Pollak, M., additional, Curhan, G., additional, Sengoge, G., additional, Bajari, T., additional, Kupczok, A., additional, von Haeseler, A., additional, Schuster, M., additional, Pfaller, W., additional, Jennings, P., additional, Weltermann, A., additional, Blake, S., additional, Sunder-Plassmann, G., additional, Kerti, A., additional, Csohany, R., additional, Wagner, L., additional, Javorszky, E., additional, Maka, E., additional, Tulassay, T., additional, Tory, K., additional, Kingswood, J., additional, Nikolskaya, N., additional, Mbundi, J., additional, Jozwiak, S., additional, Belousova, E., additional, Frost, M., additional, Kuperman, R., additional, Bebin, M., additional, Korf, B., additional, Flamini, R., additional, Kohrman, M., additional, Sparagana, S., additional, Wu, J., additional, Brechenmacher, T., additional, Stein, K., additional, Bissler, J., additional, Franz, D., additional, Zonnenberg, B., additional, Cheung, W., additional, Wang, J., additional, Lam, D., additional, Budde, K., additional, Ivanitskiy, L., additional, Sowershaewa, E., additional, Krasnova, T., additional, Samokhodskaya, L., additional, Safarikova, M., additional, Jana, R., additional, Jitka, S., additional, Obeidova, L., additional, Kohoutova, M., additional, Tesar, V., additional, Evrengul, H., additional, Ertan, P., additional, Serdaroglu, E., additional, Yuksel, S., additional, Mir, S., additional, Yang n Ergon, E., additional, Berdeli, A., additional, Zawada, A., additional, Rogacev, K., additional, Rotter, B., additional, Winter, P., additional, Fliser, D., additional, Heine, G., additional, Bataille, S., additional, Moal, V., additional, Berland, Y., additional, Daniel, L., additional, Rosado, C., additional, Bueno, E., additional, Fraile, P., additional, Lucas, C., additional, Garcoa-Cosmes, P., additional, Tabernero, J. M., additional, Gonzalez, R., additional, Garcia-Cosmes, P., additional, Silska-Dittmar, M., additional, Zaorska, K., additional, Malke, A., additional, Musielak, A., additional, Ostalska-Nowicka, D., additional, Zachwieja, J., additional, K d r, V., additional, Uz, E., additional, Yigit, A., additional, Altuntas, A., additional, Yigit, B., additional, Inal, S., additional, Sezer, M., additional, Yilmaz, R., additional, Visciano, B., additional, Porto, C., additional, Acampora, E., additional, Russo, R., additional, Riccio, E., additional, Capuano, I., additional, Parenti, G., additional, Pisani, A., additional, Feriozzi, S., additional, Perrin, A., additional, West, M., additional, Nicholls, K., additional, Torras, J., additional, Cybulla, M., additional, Conti, M., additional, Angioi, A., additional, Floris, M., additional, Melis, P., additional, Asunis, A. M., additional, Piras, D., additional, Pani, A., additional, Warnock, D., additional, Guasch, A., additional, Thomas, C., additional, Wanner, C., additional, Campbell, R., additional, Vujkovac, B., additional, Okur, I., additional, Biberoglu, G., additional, Ezgu, F., additional, Tumer, L., additional, Hasanoglu, A., additional, Bicik, Z., additional, Akin, Y., additional, Mumcuoglu, M., additional, Ecder, T., additional, Paliouras, C., additional, Mattas, G., additional, Papagiannis, N., additional, Ntetskas, G., additional, Lamprianou, F., additional, Karvouniaris, N., additional, and Alivanis, P., additional

Published
2013
Full Text
View/download PDF

92. What Would Major General John A. Lejeune Think?

Author

MARINE CORPS COMMAND AND STAFF COLL QUANTICO VA, Furman, R. D., MARINE CORPS COMMAND AND STAFF COLL QUANTICO VA, and Furman, R. D.

Abstract

Taking care of Marines and their families has been a part of the Marine Corps leaders' ethos since the Marine Corps began. The recognition of this responsibility by officers is vital to the well-being and continued success of the Marine Corps, especially because most of the men and women enlisting are under 21 years of age. These young men and women are in the formative period of their lives. Officers owe it to them, to their parents, and to the Nation, that when discharged from the service they are far better men and women physically, mentally, and morally than they were when they enlisted...and to make every effort by means of historical, educational, and patriotic addresses to cultivate in their hearts a deep abiding love of the Corps and Country. This paraphrased excerpt by Major General John A. Lejeune in Marine Corps Order No. 29, "Relations Between Officers and Men," was his vision about the responsibility officers had regarding the care of Marines in their charge. This paper asks the following question: are the young Marines of today and their families being taken care of by their government? The answer is a resounding "no." The U.S. Government and the Department of Defense (DoD) have improved military benefits since the onset of Operation Iraqi Freedom (OIF), but these benefits still remain inadequate. The DoD needs to revamp the current programs supporting casualties and their families during their recovery and follow-on care. This paper will detail travel benefits for wounded Marines families, how they need to be changed, and how these changes will benefit both Marines and the government. The specific program that will be discussed is encompassed in a document called Joint Federal Travel Regulations, Article U5246. The article is titled, "Transportation and Per Diem of Family Members of a Seriously Ill or Injured Member.", EWS Contemporary Issues Paper.

Published
2005

94. Mutations in NOTCH1PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22

Author

Arruga, F, Gizdic, B, Bologna, C, Cignetto, S, Buonincontri, R, Serra, S, Vaisitti, T, Gizzi, K, Vitale, N, Garaffo, G, Mereu, E, Diop, F, Neri, F, Incarnato, D, Coscia, M, Allan, J, Piva, R, Oliviero, S, Furman, R R, Rossi, D, Gaidano, G, and Deaglio, S

Abstract

Even if NOTCH1is commonly mutated in chronic lymphocytic leukemia (CLL), its functional impact in the disease remains unclear. Using CRISPR/Cas9-generated Mec-1 cell line models, we show that NOTCH1 regulates growth and homing of CLL cells by dictating expression levels of the tumor suppressor gene DUSP22. Specifically, NOTCH1 affects the methylation of DUSP22promoter by modulating a nuclear complex, which tunes the activity of DNA methyltransferase 3A (DNMT3A). These effects are enhanced by PEST-domain mutations, which stabilize the molecule and prolong signaling. CLL patients with a NOTCH1-mutated clone showed low levels of DUSP22 and active chemotaxis to CCL19. Lastly, in xenograft models, NOTCH1-mutated cells displayed a unique homing behavior, localizing preferentially to the spleen and brain. These findings connect NOTCH1, DUSP22, and CCL19-driven chemotaxis within a single functional network, suggesting that modulation of the homing process may provide a relevant contribution to the unfavorable prognosis associated with NOTCH1mutations in CLL.

Published
2017
Full Text
View/download PDF

95. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic leukemia.

Author

Coutre, S. E., primary, Byrd, J. C., additional, Furman, R. R., additional, Brown, J. R., additional, Benson, D. M., additional, Wagner-Johnston, N. D., additional, Flinn, I. W., additional, Kahl, B. S., additional, Spurgeon, S. E. F., additional, Lannutti, B. J., additional, Hsu, H. K. W., additional, Ulrich, R., additional, Peterman, S., additional, Holes, L., additional, Miller, L. L., additional, and Yu, A. S., additional

Published
2011
Full Text
View/download PDF

96. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study.

Author

Byrd, J. C., primary, Blum, K. A., additional, Burger, J. A., additional, Coutre, S. E., additional, Sharman, J. P., additional, Furman, R. R., additional, Flinn, I. W., additional, Grant, B. W., additional, Richards, D. A., additional, Zhao, W., additional, Heerema, N. A., additional, Johnson, A. J., additional, Izumi, R., additional, Hamdy, A., additional, and O'Brien, S. M., additional

Published
2011
Full Text
View/download PDF

97. Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.

Author

Furman, R. R., primary, Byrd, J. C., additional, Flinn, I. W., additional, Coutre, S. E., additional, Benson, D. M., additional, Brown, J. R., additional, Kahl, B. S., additional, Wagner-Johnston, N. D., additional, Giese, N. A., additional, and Yu, A. S., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results